Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialisation of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.
The ethos of their current product offering is the need to intervene early in treating glaucoma, one of the world’s leading cause of blindness. With an ultimate goal of slowing down the progression of the disease and delaying the need for more invasive treatments.
In 2001, Glaukos pioneered micro-invasive glaucoma surgery or MIGS in order to revolutionise the traditional glaucoma treatment and management paradigm. MIGS, specifically trabecular micro-bypass surgery, is now a widely accepted approach in attempting to lower intraocular pressure in mild-to-moderate open-angle glaucoma. Trabecular micro-bypass surgery can help reduce the need for more aggressive surgical options.
Glaukos launched the iStent®, the first device designed for trabecular micro-bypass surgery, in the United States in 2012. iStent inject® is the smallest medical device known to be approved by the Food and Drug Administration, or FDA, measuring 0.36 mm long and 0.23 mm wide. More than 500,000 stents have been sold since 2012.
Glaukos’s aim is to leverage the iStent® platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies that advance the existing glaucoma standard of care and enrich the lives and treatment alternatives for glaucoma patients worldwide.